摘要自从1846年本-周蛋白(Bence-Jones Protein)被发现并应用于多发性骨髓瘤的诊断和治疗以来,众多后续发现的肿瘤标志物在恶性肿瘤的发现和治疗监测中发挥着重要作用.然而,目前已发现的大部分肿瘤标志物都因其特异性和(或)灵敏性不高而在应用中受限,肿瘤标志物联合检测和临床-肿瘤标志物综合评价可弥补肿瘤标志物单方面评价的不足,这也许是未来肿瘤标志物研究的方向.

abstractsSince Bence-Jones protein was discovered and used in multiple myeloma, many tumor markers have been used in diagnosis and treatment monitoring of various cancers. However the lack of specificity and sensitivity of most tumor markers is always limiting their application in research and clinical diagnosis currently. It is predicted that the future development of tumor marker research may mainly focus on the innovation of research strategies, such as combined detection of a set of related tumors marker and comprehensive interpretation of testing results.